Edesa Biotech Free Cash Flow (FCF) History (EDSA)
Edesa Biotech reported −$6.6M in free cash flow for fiscal 2023, an increase of $5.6M from the previous fiscal year.
View full Edesa Biotech company overviewEdesa Biotech free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2023 | 2023-09-30 | −$6.6M | $5.6M | — | — |
| 2022 | 2022-09-30 | −$12.3M | $1.4M | — | — |
| 2021 | 2021-09-30 | −$13.7M | −$8.7M | — | — |
| 2020 | 2020-09-30 | −$5.0M | −$137,314 | — | −1518.00% |
| 2019 | 2019-09-30 | −$4.9M | $144,433 | — | −1181.37% |
| 2018 · Dec 31 | 2018-12-31 | −$1.3M | — | — | — |
| 2018 · Sep 30 | 2018-09-30 | −$5.0M | $4,067 | — | — |
| 2017 | 2017-09-30 | −$5.0M | −$94,482 | — | −10004.76% |
| 2016 | 2016-09-30 | −$4.9M | −$220,916 | — | −385.94% |
| 2015 | 2015-09-30 | −$4.7M | — | — | −617.77% |
| 2014 | 2014-08-31 | −$4.5M | −$1.7M | — | −1221.55% |
| 2013 | 2013-08-31 | −$2.8M | $1.2M | — | −514.30% |
| 2012 | 2012-08-31 | −$4.0M | — | — | −1407.48% |
Edesa Biotech quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2023 | 2023-09-30 | −$1.5M | $4.2M | — | — |
| Q3 2023 | 2023-06-30 | −$1.8M | $1.2M | — | — |
| Q2 2023 | 2023-03-31 | −$1.6M | −$1.2M | — | — |
| Q1 2023 | 2022-12-31 | −$1.8M | $1.4M | — | — |
| Q4 2022 | 2022-09-30 | −$5.6M | −$5.3M | — | — |
| Q3 2022 | 2022-06-30 | −$3.0M | $94,881 | — | — |
| Q2 2022 | 2022-03-31 | −$417,853 | $6.8M | — | — |
| Q1 2022 | 2021-12-31 | −$3.2M | −$199,090 | — | — |
| Q4 2021 | 2021-09-30 | −$356,785 | $1.3M | — | — |
| Q3 2021 | 2021-06-30 | −$3.1M | −$1.8M | — | — |
| Q2 2021 | 2021-03-31 | −$7.2M | −$6.0M | — | — |
| Q1 2021 | 2020-12-31 | −$3.0M | −$2.2M | — | — |
| Q4 2020 | 2020-09-30 | −$1.7M | — | — | −335393.60% |
| Q3 2020 | 2020-06-30 | −$1.4M | — | — | −1230.39% |
| Q2 2020 | 2020-03-31 | −$1.2M | −$768,228 | — | −1059.82% |
| Q1 2020 | 2019-12-31 | −$789,712 | −$401,700 | — | −732.57% |
| Q1 2019 | 2019-03-31 | −$403,044 | $1.2M | — | — |
| Q4 2018 | 2018-12-31 | −$388,012 | $791,218 | — | — |
| Q2 2018 | 2018-03-31 | −$1.6M | −$240,914 | — | −2434.79% |
| Q1 2018 | 2017-12-31 | −$1.2M | $270,228 | — | −5755.99% |
| Q4 2017 | 2017-09-30 | −$1.2M | $79,597 | — | — |
| Q3 2017 | 2017-06-30 | −$1.0M | $83,226 | — | — |
| Q2 2017 | 2017-03-31 | −$1.3M | −$157,411 | — | −2092.41% |
| Q1 2017 | 2016-12-31 | −$1.4M | −$99,894 | — | −1021.78% |
| Q4 2016 | 2016-09-30 | −$1.3M | −$312,386 | — | −470.51% |
| Q3 2016 | 2016-06-30 | −$1.1M | −$36,914 | — | −606.35% |
| Q2 2016 | 2016-03-31 | −$1.2M | $153,555 | — | −355.83% |
| Q1 2016 | 2015-12-31 | −$1.3M | −$25,171 | — | −276.46% |
| Q4 2015 | 2015-09-30 | −$986,694 | — | — | −491.74% |
| Q3 2015 | 2015-06-30 | −$1.1M | $66,724 | — | −672.68% |
| Q2 2015 | 2015-03-31 | −$1.3M | $200,067 | — | −700.73% |
| Q1 2015 | 2014-12-31 | −$1.3M | −$28,376 | — | −622.77% |
| Q4 2014 | 2014-08-31 | −$607,067 | — | — | −480.28% |
| Q3 2014 | 2014-06-30 | −$1.1M | — | — | −1554.86% |
| Q2 2014 | 2014-03-31 | −$1.5M | — | — | −1324.48% |
| Q1 2014 | 2013-12-31 | −$1.3M | — | — | −2203.17% |
Edesa Biotech free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$5.0M to −$6.6M, a net decrease of $1.6M. Edesa Biotech's latest reported quarter, Q4 2023, generated −$1.5M in free cash flow, an increase of $4.2M year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Edesa Biotech source filings ↗